WINT Quote, Financials, Valuation and Earnings

ANI Pharmaceuticals has a net margin of -- compared to Windtree Therapeutics's net margin of -16.29%. Windtree Therapeutics's return on equity of -- beat ANI Pharmaceuticals's return on equity of -1.54%.

Windtree Therapeutics has a consensus price target of --, signalling upside risk potential of 1976.54%. On the other hand ANI Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 47.34%. Given that Windtree Therapeutics has higher upside potential than ANI Pharmaceuticals, analysts believe Windtree Therapeutics is more attractive than ANI Pharmaceuticals.

Windtree Therapeutics has a beta of 0.540, which suggesting that the stock is 45.975% less volatile than S&P 500. In comparison ANI Pharmaceuticals has a beta of 0.729, suggesting its less volatile than the S&P 500 by 27.112%.

Windtree Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Windtree Therapeutics pays -- of its earnings as a dividend. ANI Pharmaceuticals pays out 8.65% of its earnings as a dividend. ANI Pharmaceuticals's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Windtree Therapeutics quarterly revenues are --, which are smaller than ANI Pharmaceuticals quarterly revenues of $148.3M. Windtree Therapeutics's net income of -$2.7M is higher than ANI Pharmaceuticals's net income of -$24.2M. Notably, Windtree Therapeutics's price-to-earnings ratio is -- while ANI Pharmaceuticals's PE ratio is 53.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Windtree Therapeutics is 0.26x versus 1.86x for ANI Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Armata Pharmaceuticals has a net margin of -- compared to Windtree Therapeutics's net margin of --. Windtree Therapeutics's return on equity of -- beat Armata Pharmaceuticals's return on equity of --.

Windtree Therapeutics has a consensus price target of --, signalling upside risk potential of 1976.54%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $7.00 which suggests that it could grow by 258.97%. Given that Windtree Therapeutics has higher upside potential than Armata Pharmaceuticals, analysts believe Windtree Therapeutics is more attractive than Armata Pharmaceuticals.

Windtree Therapeutics has a beta of 0.540, which suggesting that the stock is 45.975% less volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.777, suggesting its less volatile than the S&P 500 by 22.301%.

Windtree Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Windtree Therapeutics pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Windtree Therapeutics quarterly revenues are --, which are smaller than Armata Pharmaceuticals quarterly revenues of --. Windtree Therapeutics's net income of -$2.7M is higher than Armata Pharmaceuticals's net income of -$5.5M. Notably, Windtree Therapeutics's price-to-earnings ratio is -- while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Windtree Therapeutics is 0.26x versus 706.46x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -- compared to Windtree Therapeutics's net margin of --. Windtree Therapeutics's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Windtree Therapeutics has a consensus price target of --, signalling upside risk potential of 1976.54%. On the other hand Perspective Therapeutics has an analysts' consensus of -- which suggests that it could grow by 466.67%. Given that Windtree Therapeutics has higher upside potential than Perspective Therapeutics, analysts believe Windtree Therapeutics is more attractive than Perspective Therapeutics.

Windtree Therapeutics has a beta of 0.540, which suggesting that the stock is 45.975% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

Windtree Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Windtree Therapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Windtree Therapeutics quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Windtree Therapeutics's net income of -$2.7M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Windtree Therapeutics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Windtree Therapeutics is 0.26x versus 15.39x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to Windtree Therapeutics's net margin of 18.02%. Windtree Therapeutics's return on equity of -- beat Protalix BioTherapeutics's return on equity of -29.54%.

Windtree Therapeutics has a consensus price target of --, signalling upside risk potential of 1976.54%. On the other hand Protalix BioTherapeutics has an analysts' consensus of -- which suggests that it could grow by 695.46%. Given that Windtree Therapeutics has higher upside potential than Protalix BioTherapeutics, analysts believe Windtree Therapeutics is more attractive than Protalix BioTherapeutics.

Windtree Therapeutics has a beta of 0.540, which suggesting that the stock is 45.975% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.741, suggesting its less volatile than the S&P 500 by 25.895%.

Windtree Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Windtree Therapeutics pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Windtree Therapeutics quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18M. Windtree Therapeutics's net income of -$2.7M is lower than Protalix BioTherapeutics's net income of $3.2M. Notably, Windtree Therapeutics's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 115.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Windtree Therapeutics is 0.26x versus 3.03x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.